“Reta”, “R3”, “ratatouille”… If you spend any time in GLP-1 communities, you’ve seen these code words. They all point to the same molecule: retatrutide, Eli Lilly’s triple agonist showing the largest weight losses ever measured in clinical trials — and approved nowhere. Here is what the studies actually show, where approval stands, and why the nicknames exist in the first place.
Why code words?
On social networks and forums, openly discussing an unapproved medication exposes posts to moderation or outright removal. Communities have learned to slip past the filters with nicknames: “reta”, “R3” (most likely for the third generation, after the dual agonists), or the more playful “ratatouille”. The phenomenon says a lot: many people are already testing this molecule outside any legal or medical framework — more on that below, because it’s the real story.
What is retatrutide?
Retatrutide is a triple agonist: it simultaneously activates the GLP-1 and GIP receptors (like Mounjaro®‘s tirzepatide) and — this is the new part — the glucagon receptor, involved in energy expenditure. It’s a weekly injection, developed by Eli Lilly, currently in phase 3 (the TRIUMPH programme, over 5,800 participants).
What the trials show — unprecedented numbers
The published results are without precedent:
- Phase 2 (New England Journal of Medicine, 2023): about 24% average weight loss at 48 weeks at the highest dose (12 mg) — with no plateau reached by the end of the trial.
- TRIUMPH-1 (phase 3, results May 2026): 28.3% on average at 80 weeks and 30.3% at 104 weeks at the highest doses — in the range previously reported for bariatric surgery.
- TRIUMPH-2 and TRIUMPH-3 (July 2026): efficacy confirmed in people with severe obesity, type 2 diabetes or established cardiovascular disease (about 22.6% at 80 weeks in TRIUMPH-3).
A note on method: comparing these numbers with Wegovy® or Mounjaro® across different trials is unreliable (different populations and protocols). But the order of magnitude is clear, and side effects remain dominated by the digestive system, as with the rest of the class.
Where does approval stand?
Nowhere, for now. Eli Lilly plans to file with the US FDA in early 2027, with potential US approval in late 2027 — Europe would follow, with the EMA’s own review timeline and, later, national coverage decisions. Until then, the only legal route of access is enrolling in a clinical trial.
The grey market: what a “research use only” vial does (and doesn’t) guarantee
Alongside the trials, a grey market has taken shape: websites sell “retatrutide” in vials labelled research use only, and a large number of people inject it without any medical framework. Three factual realities to keep in mind:
- No quality control: purity, actual dose and sterility are unverified — independent testing of grey-market peptides regularly finds underdosed, overdosed or contaminated products.
- No complete track record, no regulatory review: the phase 3 programme isn’t finished, and no agency has yet examined its safety data. Whoever uses the molecule today does so without that hindsight, and without the follow-up built into the trials.
- No medical circuit: titration, side-effect monitoring and what-to-do-when rest entirely on the user — and importing an unapproved medicine is illegal in many countries (including France), outside any legal or health-system protection.
The nicknames tell you how widespread this is; they tell you nothing about what a given vial actually contains.
And if you have already made that choice, one thing is worth knowing: medical confidentiality applies. Telling your doctor or pharmacist what you inject exposes you to nothing — and it’s the only way a professional can take it into account (interactions, digestive effects, surgery or pregnancy to plan around). It’s also what approval will change, when it comes: a product with guaranteed contents, organised follow-up, pharmacovigilance.
What exists inside the legal framework in 2026
There are real reasons people look at retatrutide: reported efficacy, but also the cost and access conditions of current treatments. In 2026, two molecules from the same family are approved, supervised and available on prescription: Wegovy® and Mounjaro®. If your current treatment isn’t delivering, an adjustment (dose or molecule) is a conversation for your doctor — and the only route where what you inject is guaranteed to be what the label says. Living in France? See how coverage works there.
On the tracking side, the Doza app is a journal, not a judge: retatrutide is in its catalogue, clearly labelled “Clinical trial”, and the weekly reminders, injection sites, weight and estimated level curve work just like for any other molecule. The app never suggests a dose or a titration schedule, and your measurements and doses never leave your iPhone: no account, no cloud — your data is nobody’s business but yours.
FAQ — retatrutide
What do “reta”, “R3” and “ratatouille” mean?
They’re nicknames for retatrutide used on forums and social networks to get around content moderation on unapproved medications. “R3” most likely refers to the third generation of these treatments; “ratatouille” is just wordplay.
Is retatrutide approved anywhere?
No — nowhere in the world. The FDA filing is planned for early 2027; Europe would come later, after the EMA’s review. Clinical trials are the only legal way to access it today.
Is retatrutide more effective than Wegovy or Mounjaro?
The TRIUMPH trials show average losses never reached before (up to 30% at 104 weeks), above the published figures for current molecules — but head-to-head comparisons don’t exist yet, and only regulatory review will settle the benefit-risk balance.
What are the risks of buying “reta” online?
Products with no quality control (dose, purity, sterility), no medical follow-up, no regulatory review of the safety data and legal exposure on import: the risks stack up, for a benefit the vial you receive may not even contain.
Can you track retatrutide in an app?
Yes: the Doza app includes it in its catalogue, labelled “Clinical trial”, as a pure journal — doses, weight, injection sites and an estimated level curve, never any dose advice. Your measurements and doses never leave your iPhone — no account, no cloud.
Sources: Jastreboff et al., NEJM 2023 (phase 2) · Eli Lilly — TRIUMPH-1 results, May 2026 · Eli Lilly — TRIUMPH-2 and TRIUMPH-3, July 2026. General information only: this is neither medical advice nor an encouragement to use an unapproved substance.